Help -- or at least cash -- is on the wayThe California Institute for Regenerative Medicine (CIRM) announced yesterday that it has received $275 million in fresh funding from a recent sale of state bonds, saving the state stem-cell agency from a cash crunch that would have left it without money to fund new research by next fall.
Robert Klein, the Palo Alto real-estate magnate who led the successful 2004 ballot-initiative campaign to create a $3 billion state stem-cell funding agency and then steered the agency through its first years as chairman, has announced that he will step down from his leadership post at the end of 2010.Klein's decision to give up the chairmanship of the California Institute for Regenerative Medicine (CIRM), first reported by John Simpson of Consumer Watchdog, is a milestone for the stem-cell agen
Marie CseteThe chief scientific officer at California's stem-cell agency has announced that she will step down from her position in a little over a month.Marie Csete, who had been at the San Francisco-based California Institute for Regenerative Medicine (CIRM) for slightly more than a year, has so far offered no specific reasons for leaving the agency, which was created to fund stem-cell research through Proposition 71. Csete was highly respected in the medical-science community, and news of her
Tempest in a petri dishIt's been a tough week in the news for California's San Francisco-based stem-cell research agency.Last week, it was revealed that the California Institute for Regenerative Medicine (CIRM) -- created to fund stem-cell research through Proposition 71, the 2004 state ballot initiative -- was losing its highly respected chief scientist, Marie Csete. Since then, a state watchdog agency has suggested a number of drastic changes to how CIRM operates. And to top it off, Csete, in
In an April cover story, we looked at the dilemma facing the California Institute for Regenerative Medicine (CIRM), the state agency created through Proposition 71 to fund stem-cell research: Should the landmark agency direct the remainder of its $3 billion in research funds towards "adult" stem cells -- which are closer to clinical applications, albeit for less serious ailments -- or to embryonic stem cells, which offer hope to intractable degenerative diseases such as juvenile diabetes and mul
foam order.com
